BamSEC and AlphaSense Join Forces
Learn More

Clinical Data Inc

Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 8-K 45 pages Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted and Filed Separately With the Securities and Exchange Commission Pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as Amended. Commercial Manufacturing Services Agreement August 18, 2010
12/34/56
EX-10.1
from 8-K 40 pages Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted and Filed Separately With the Securities and Exchange Commission Pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as Amended. Commercial Supply Agreement by and Between Pgxhealth, LLC and Scinopharm Taiwan, Ltd. August 19, 2010 Commercial Supply Agreement Article 1 Definitions
12/34/56
EX-10.4
from 8-K 7 pages Noncompetition and Nonsolicitation Agreement
12/34/56
EX-10.3
from 8-K 19 pages Security Agreement
12/34/56
EX-10.2
from 8-K 5 pages Secured Promissory Note
12/34/56
EX-10.1
from 8-K 6 pages Secured Promissory Note
12/34/56
EX-10.1
from 10-Q 13 pages Clinical Data, Inc. Amended and Restated 2005 Equity Incentive Plan Article 1. Background and Purpose of the Plan Article 2. Share Limits
12/34/56
EX-10.1
from 10-Q 25 pages Executive Employment Agreement
12/34/56
EX-10.5
from 10-Q 18 pages Clinical Data, Inc. Amended and Restated 2005 Equity Incentive Plan Article 1. Background and Purpose of the Plan Article 2. Share Limits
12/34/56
EX-10.10
from S-4/A 4 pages 2. Interest Rate. From the Date Hereof Until Such Time as All Principal, Interest and Other Amounts Outstanding Hereunder Are Unconditionally and Irrevocably Paid and Performed in Full, Interest Shall Accrue on the Unpaid Principal Amount (Computed on the Basis of the Actual Number of Days Elapsed Over a Year of 365 or 366 Days, as Applicable) Equal to a Fixed Rate of Seven Percent (7.0%) Per Annum. 3. Payments. 3.1 Payment of Principal and Interest. All Outstanding Principal and Accrued Interest Under This Note Shall Be Immediately Due and Payable on the Maturity Date (As Defined Below)
12/34/56
EX-10.9
from S-4/A 2 pages Amendment No. 2 to Term Note
12/34/56
EX-10.7
from S-4/A 2 pages Amendment No. 1 to Term Note
12/34/56
EX-10.3B
from S-4 2 pages Avalon Pharmaceuticals, Inc. 20358 Seneca Meadows Parkway Germantown, MD 20876 November 17, 2008
12/34/56
EX-10.1
from 10-Q 24 pages Amended and Restated Executive Employment Agreement
12/34/56
EX-10.11
from 10-K 24 pages Amended and Restated Executive Employment Agreement
12/34/56
EX-10.8
from 10-K 25 pages Executive Employment Agreement
12/34/56
EX-10.1
from 10-Q 19 pages Clinical Data, Inc. Amended and Restated 2005 Equity Incentive Plan Article 1. Background and Purpose of the Plan Article 2. Share Limits
12/34/56
EX-10.1
from 10-Q 25 pages Executive Employment Agreement
12/34/56
EX-10.3
from 10-Q ~20 pages Ex-10.3 - Amended and Restated 2005 Equity Incentive Plan
12/34/56
EX-10.2
from 10-Q ~5 pages Ex-10.2 - Employment Offer Letter Dated August 7, 2006
12/34/56